Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1

Marlies V. Hager, Lachlan Clydesdale, Samuel H. Gellman, Patrick M Sexton, Denise Wootten

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that is a major therapeutic target for the treatment of type 2 diabetes. Activation of this receptor promotes insulin secretion and blood glucose regulation. The GLP-1R can initiate signaling through several intracellular pathways upon activation by GLP-1. GLP-1R ligands that preferentially stimulate subsets among the natural signaling pathways ("biased agonists") could be useful as tools for elucidating the consequences of specific pathways and might engender therapeutic agents with tailored effects. Using HEK-293 cells recombinantly expressing human GLP-1R, we have previously reported that backbone modification of GLP-1, via replacement of selected α-amino acid residues with β-amino acid residues, generates GLP-1 analogues with distinctive preferences for promoting G protein activation versus β-arrestin recruitment. Here, we have explored the influence of cell background across these two parameters and expanded our analysis to include affinity and other key signaling pathways (intracellular calcium mobilization and ERK phosphorylation) using recombinant human GLP-1R expressed in a CHO cell background, which has been used extensively to demonstrate biased agonism of GLP-1R ligands. The new data indicate that α/β-peptide analogues of GLP-1 exhibit a range of distinct bias profiles relative to GLP-1 and that broad assessment of signaling endpoints is required to reveal the spectrum of behavior of modified peptides. These results support the view that backbone modification via α. →. β amino acid replacement can enable rapid discovery of peptide hormone analogues that display substantial signal bias at a cognate GPCR.

Original languageEnglish
Pages (from-to)99-108
Number of pages10
JournalBiochemical Pharmacology
Volume136
DOIs
Publication statusPublished - 15 Jul 2017

Keywords

  • Biased agonism
  • Cell signaling
  • G protein coupled receptor
  • Glucagon-like peptide-1 receptor
  • Peptides

Cite this

@article{315785ed6b114c92a69920d4a3ea4d5e,
title = "Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1",
abstract = "The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that is a major therapeutic target for the treatment of type 2 diabetes. Activation of this receptor promotes insulin secretion and blood glucose regulation. The GLP-1R can initiate signaling through several intracellular pathways upon activation by GLP-1. GLP-1R ligands that preferentially stimulate subsets among the natural signaling pathways ({"}biased agonists{"}) could be useful as tools for elucidating the consequences of specific pathways and might engender therapeutic agents with tailored effects. Using HEK-293 cells recombinantly expressing human GLP-1R, we have previously reported that backbone modification of GLP-1, via replacement of selected α-amino acid residues with β-amino acid residues, generates GLP-1 analogues with distinctive preferences for promoting G protein activation versus β-arrestin recruitment. Here, we have explored the influence of cell background across these two parameters and expanded our analysis to include affinity and other key signaling pathways (intracellular calcium mobilization and ERK phosphorylation) using recombinant human GLP-1R expressed in a CHO cell background, which has been used extensively to demonstrate biased agonism of GLP-1R ligands. The new data indicate that α/β-peptide analogues of GLP-1 exhibit a range of distinct bias profiles relative to GLP-1 and that broad assessment of signaling endpoints is required to reveal the spectrum of behavior of modified peptides. These results support the view that backbone modification via α. →. β amino acid replacement can enable rapid discovery of peptide hormone analogues that display substantial signal bias at a cognate GPCR.",
keywords = "Biased agonism, Cell signaling, G protein coupled receptor, Glucagon-like peptide-1 receptor, Peptides",
author = "Hager, {Marlies V.} and Lachlan Clydesdale and Gellman, {Samuel H.} and Sexton, {Patrick M} and Denise Wootten",
year = "2017",
month = "7",
day = "15",
doi = "10.1016/j.bcp.2017.03.018",
language = "English",
volume = "136",
pages = "99--108",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier",

}

Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1. / Hager, Marlies V.; Clydesdale, Lachlan; Gellman, Samuel H.; Sexton, Patrick M; Wootten, Denise.

In: Biochemical Pharmacology, Vol. 136, 15.07.2017, p. 99-108.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Characterization of signal bias at the GLP-1 receptor induced by backbone modification of GLP-1

AU - Hager, Marlies V.

AU - Clydesdale, Lachlan

AU - Gellman, Samuel H.

AU - Sexton, Patrick M

AU - Wootten, Denise

PY - 2017/7/15

Y1 - 2017/7/15

N2 - The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that is a major therapeutic target for the treatment of type 2 diabetes. Activation of this receptor promotes insulin secretion and blood glucose regulation. The GLP-1R can initiate signaling through several intracellular pathways upon activation by GLP-1. GLP-1R ligands that preferentially stimulate subsets among the natural signaling pathways ("biased agonists") could be useful as tools for elucidating the consequences of specific pathways and might engender therapeutic agents with tailored effects. Using HEK-293 cells recombinantly expressing human GLP-1R, we have previously reported that backbone modification of GLP-1, via replacement of selected α-amino acid residues with β-amino acid residues, generates GLP-1 analogues with distinctive preferences for promoting G protein activation versus β-arrestin recruitment. Here, we have explored the influence of cell background across these two parameters and expanded our analysis to include affinity and other key signaling pathways (intracellular calcium mobilization and ERK phosphorylation) using recombinant human GLP-1R expressed in a CHO cell background, which has been used extensively to demonstrate biased agonism of GLP-1R ligands. The new data indicate that α/β-peptide analogues of GLP-1 exhibit a range of distinct bias profiles relative to GLP-1 and that broad assessment of signaling endpoints is required to reveal the spectrum of behavior of modified peptides. These results support the view that backbone modification via α. →. β amino acid replacement can enable rapid discovery of peptide hormone analogues that display substantial signal bias at a cognate GPCR.

AB - The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor that is a major therapeutic target for the treatment of type 2 diabetes. Activation of this receptor promotes insulin secretion and blood glucose regulation. The GLP-1R can initiate signaling through several intracellular pathways upon activation by GLP-1. GLP-1R ligands that preferentially stimulate subsets among the natural signaling pathways ("biased agonists") could be useful as tools for elucidating the consequences of specific pathways and might engender therapeutic agents with tailored effects. Using HEK-293 cells recombinantly expressing human GLP-1R, we have previously reported that backbone modification of GLP-1, via replacement of selected α-amino acid residues with β-amino acid residues, generates GLP-1 analogues with distinctive preferences for promoting G protein activation versus β-arrestin recruitment. Here, we have explored the influence of cell background across these two parameters and expanded our analysis to include affinity and other key signaling pathways (intracellular calcium mobilization and ERK phosphorylation) using recombinant human GLP-1R expressed in a CHO cell background, which has been used extensively to demonstrate biased agonism of GLP-1R ligands. The new data indicate that α/β-peptide analogues of GLP-1 exhibit a range of distinct bias profiles relative to GLP-1 and that broad assessment of signaling endpoints is required to reveal the spectrum of behavior of modified peptides. These results support the view that backbone modification via α. →. β amino acid replacement can enable rapid discovery of peptide hormone analogues that display substantial signal bias at a cognate GPCR.

KW - Biased agonism

KW - Cell signaling

KW - G protein coupled receptor

KW - Glucagon-like peptide-1 receptor

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=85017351662&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2017.03.018

DO - 10.1016/j.bcp.2017.03.018

M3 - Article

VL - 136

SP - 99

EP - 108

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -